Methods of using probenecid for treatment of coronavirus infections
US11116737B1 · kind B1 · utility
Assignee
Inventors
Key dates
| Filing date | May 15, 2020 |
| Grant date | Sep 14, 2021 |
| Priority date | — |
| Expiry date | May 15, 2040 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K9/0053
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Compositions and methods of treating a subject for a coronavirus infection are provided. The methods typically include administering the subject an effective amount of probenecid, a metabolite or analog thereof, or a pharmaceutically acceptable salt thereof. The methods can by therapeutic and/or prophylactic. The amount of probenecid or a pharmaceutically acceptable salt thereof can be effective to, for example, reduce viral replication, reduce one or more symptoms of disease, disorder, or illness associated with virus, or a combination thereof. In preferred embodiments, the virus is a Severe acute respiratory syndrome-related coronavirus such as SARS-CoV-2 or SARS-CoV, a Middle East respiratory syndrome-related coronavirus such as MERS-CoV, or a coronavirus that causes the common cold.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.